CytoDyn (CYDY) Retained Earnings (2011 - 2026)
CytoDyn's (CYDY) quarterly Retained Earnings came in at $815.0 million in Q1 2026, up 3.47% YoY from $787.6 million in Q1 2025, and up 188.98% on a QoQ basis from -$915.9 million in Q4 2025.
CytoDyn (CYDY) Retained Earnings (2011 - 2026) Analysis & Trends
CytoDyn (CYDY) has 16 years of Retained Earnings data on file, last reported at $815.0 million in Q1 2026.
- Quarterly Retained Earnings rose 3.47% year-over-year to $815.0 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $815.0 million (up 3.47% YoY) and the FY2025 annual result came in at $790.5 million, up 2.17% from the prior year.
- Retained Earnings improved to $815.0 million in Q1 2026, from -$915.9 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $815.0 million in Q1 2026 to a low of -$915.9 million in Q4 2025.
- A 5-year average of -$81.9 million and a median of -$782.9 million in 2022 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 221.19% in 2022, down 236.48% in 2022.
- Tracing CYDY's Retained Earnings over 5 years: stood at -$809.4 million in 2022, then surged by 192.35% to $747.5 million in 2023, then climbed by 5.22% to $786.5 million in 2024, then slumped by 216.46% to -$915.9 million in 2025, then soared by 188.98% to $815.0 million in 2026.
- The last three Retained Earnings figures came in at $815.0 million (Q1 2026), -$915.9 million (Q4 2025), and $792.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - | 814.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 814.98 Mn |
| Nov 30, 2025 | -915.93 Mn |
| Aug 31, 2025 | 792.56 Mn |
| May 31, 2025 | 790.50 Mn |
| Feb 28, 2025 | 787.62 Mn |
| Nov 30, 2024 | 786.46 Mn |
| Aug 31, 2024 | -872.30 Mn |
| May 31, 2024 | 773.71 Mn |
| Feb 29, 2024 | -874.70 Mn |
| Nov 30, 2023 | 747.47 Mn |
| Aug 31, 2023 | -853.30 Mn |
| May 31, 2023 | -841.69 Mn |
| Feb 28, 2023 | -823.10 Mn |
| Nov 30, 2022 | -809.35 Mn |
| Aug 31, 2022 | -782.86 Mn |
| May 31, 2022 | 671.01 Mn |
| Feb 28, 2022 | -782.90 Mn |
| Nov 30, 2021 | -639.94 Mn |
| Aug 31, 2021 | 573.60 Mn |
| May 31, 2021 | -553.68 Mn |